Form 4: STERIS Executive's Share Vesting & Tax Withholding

STERIS plc's SVP and President, Healthcare, Cary L. Majors, reported the vesting of restricted shares and the withholding of 303 shares for tax obligations.

Summary

• Cary L. Majors, SVP and President, Healthcare at STERIS plc, reported a transaction on October 1, 2025.
• 303 ordinary shares were withheld to cover tax liabilities from the vesting of 692 restricted shares.
• The 692 restricted shares, awarded on October 1, 2021, vested on October 1, 2025.
• The value of the vested shares was determined by the NYSE closing market price on October 1, 2025.
• Following this transaction, Mr. Majors directly holds 13,427 ordinary shares, of which 10,138 are restricted.
• The restricted shares vest in tranches: 2,697 on June 1, 2026; 2,140 on June 2, 2026; 2,379 on June 4, 2027; and 2,922 on June 5, 2028.
• Additionally, Mr. Majors indirectly holds 67 ordinary share equivalents in the STERIS Corporation 401(k) Plan as of October 2, 2025.

Sentiment

Score: 5

Explanation: This is a routine executive compensation event (vesting and tax withholding) and does not present significant positive or negative news that would alter the company's fundamental outlook.

Positives

• The vesting of 692 restricted shares for Cary L. Majors indicates the successful maturation of a long-term incentive compensation plan.
• The executive continues to hold a significant number of shares, including 10,138 restricted shares, aligning management interests with shareholder value.

Negatives

• 303 shares were disposed of to cover tax liabilities, reducing the immediate beneficial ownership.

Risks

• NA

Future Outlook

The remaining 10,138 restricted ordinary shares held by Mr. Majors are scheduled to vest in tranches between June 2026 and June 2028, indicating continued long-term incentive alignment.

Management Comments

• NA

Industry Context

This filing reflects a routine executive compensation event, common across publicly traded companies, where restricted stock units vest and a portion is withheld for tax purposes. It does not provide broader industry trends.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation, aligning management incentives with long-term shareholder value through continued share ownership.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• Lapse of restrictions on 2,697 ordinary shares on June 1, 2026.
• Lapse of restrictions on 2,140 ordinary shares on June 2, 2026.
• Lapse of restrictions on 2,379 ordinary shares on June 4, 2027.
• Lapse of restrictions on 2,922 ordinary shares on June 5, 2028.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of restricted shares and subsequent tax withholding. It does not present new information that would fundamentally alter the investment thesis for STERIS plc. The executive's continued significant share ownership, including future vesting tranches, suggests ongoing alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing does not provide a catalyst for a change in investment strategy.

Keywords

STERIS, STE, Form 4, insider transaction, share vesting, executive compensation, restricted stock, tax withholding